Physician profile
David Watson
NPI 1568420909
$1,728.52
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $311 · 2021: $319 · 2022: $433 · 2023: $312 · 2024: $19.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $309 · Education: $23.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $308.53 |
| Education | $23.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $566.44 | 2019-2023 | Liletta, Lo Loestrin Fe, Orilissa |
| Eisai INC. | $181.92 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $124.24 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $91.63 | 2020-2022 | |
| Ascend Therapeutics US, LLC | $86.45 | 2019-2021 | |
| Therapeuticsmd, INC. | $74.91 | 2019-2022 | |
| Hologic Sales and Service, LLC | $74.00 | 2021-2024 | Omni Hysteroscope, Novasure, Myosure Tissue Removal Device |
| Vertical Pharmaceuticals, LLC | $64.21 | 2019 | |
| Allergan, INC. | $53.39 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $49.45 | 2020-2022 | |
| Astellas Pharma US INC | $43.82 | 2022-2023 | Veozah |
| Idorsia Pharmaceuticals US INC | $36.83 | 2023 | Quviviq |
| Avion Pharmaceuticals | $34.74 | 2021-2022 | |
| Organon LLC | $32.56 | 2021-2022 | |
| Myovant Sciences INC. | $26.88 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dysis Medical, INC. | $25.02 | 2021 | |
| Coloplast Corp | $23.84 | 2022 | |
| Sumitomo Pharma America, INC. | $23.81 | 2023 | Myfembree |
| Pfizer INC. | $23.04 | 2023 | |
| Evofem Biosciences, INC. | $18.42 | 2021 | |
| Exact Sciences Corporation | $18.02 | 2023 | Cologuard Collection Kit |
| Shield Therapeutics INC | $16.85 | 2023 | Accrufer |
| Coopersurgical, INC. | $14.05 | 2021 | |
| Lupin INC. | $12.44 | 2021 | |
| Acelrx Pharmaceuticals, INC. | $11.56 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,931,682.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.